PRF Technologies reports expanded preclinical head-to-head data for PRF-110 vs Zynrelef in porcine pain model

• PRF Technologies reported expanded preclinical head-to-head results for PRF-110 versus Heron’s ZYNRELEF, adding PK and tissue-distribution findings to earlier efficacy data.
• Pain relief performance matched the approved benchmark in a porcine post-operative pain model, supporting PRF-110’s competitiveness in long-acting local analgesia.
• Drug behavior suggested a more gradual release with stronger local tissue retention than ZYNRELEF, a profile aligned with longer-lasting surgical-site pain control.
• Management framed the readout as supportive of differentiation, with plans to advance PRF-110 through additional studies across broader surgical settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PRF Technologies Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250830PRIMZONEFULLFEED9752111) on June 25, 2026, and is solely responsible for the information contained therein.